<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Konradi, Alexandra O.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Promises and Questions in Renal Denervation for Resistant Hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">30-31</style></pages><abstract><style  face="normal" font="default" size="100%">Renal denervation (RDN) is a promising emerging treatment option for resistant hypertension, as well as other diseases that appear to be associated with sympathetic activation. This article discusses guideline recommendations for the diagnosis and conventional treatment of resistant hypertension; data of RDN efficacy and safety; investigational indications for RDN therapy; as well as the reasons behind the popularity and success of RDN.</style></abstract><number><style face="normal" font="default" size="100%">15</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>